FTC/TDF+MK-0518+Losartan
ApprovedSmall molecule
FTC/TDF+MK-0518+Losartan is one of 17 small molecule programs targeting Cognitive Disorder. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Cognitive Disorder
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Namenda
AbbViePhase 3
EFV/FTC/TDF
GileadApproved
Paxil
SSebela Pharmaceuticals Development LLC
Phase 2
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
FTC/TDF+MK-0518+Losartan
FFelipe Garcia
Approved
Biological Check-up
UUniversity Hospital, Bordeaux
Phase 2
MMH-MAP
MMateria Medica Holding
Phase 3
Feraheme
AAzurity Pharmaceuticals
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for FTC/TDF+MK-0518+Losartan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- FFelipe Garcia